These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31035359)

  • 1. ARNi: A Novel Approach to Counteract Cardiovascular Diseases.
    Volpe M; Rubattu S; Battistoni A
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
    Sutanto H; Dobrev D; Heijman J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
    Volpe M; Tocci G; Battistoni A; Rubattu S
    High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):241-6. PubMed ID: 26100410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M
    Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.
    Volpe M; Santolamazza C; Tocci G
    Curr Cardiol Rep; 2016 Dec; 18(12):127. PubMed ID: 27796865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.
    Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
    Blood Press; 2012 Dec; 21(6):329-30. PubMed ID: 23210746
    [No Abstract]   [Full Text] [Related]  

  • 11. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ARNI, new abbreviation for a new class of treatment of heart failure].
    Karimzadeh S; Mustafić H; Stampfli Andres T
    Rev Med Suisse; 2017 Mar; 13(552):496-499. PubMed ID: 28714615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
    Leong DP; McMurray JJV; Joseph PG; Yusuf S
    J Am Coll Cardiol; 2019 Aug; 74(5):683-698. PubMed ID: 31370961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.
    Ambrosy AP; Mentz RJ; Fiuzat M; Cleland JGF; Greene SJ; O'Connor CM; Teerlink JR; Zannad F; Solomon SD
    Eur J Heart Fail; 2018 Jun; 20(6):963-972. PubMed ID: 29464817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction.
    Nasrallah D; Abdelhamid A; Tluli O; Al-Haneedi Y; Dakik H; Eid AH
    Pharmacol Res; 2024 Jun; 204():107210. PubMed ID: 38740146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers.
    Mollace V; Gliozzi M; Capuano A; Rossi F
    Int J Cardiol; 2017 Jan; 226():126-131. PubMed ID: 27075034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the renin-angiotensin-aldosterone system in heart failure.
    George J; Struthers AD; Lang CC
    Curr Atheroscler Rep; 2014 Apr; 16(4):403. PubMed ID: 24510580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
    Bayes-Genis A; Morant-Talamante N; Lupón J
    Curr Heart Fail Rep; 2016 Aug; 13(4):151-7. PubMed ID: 27260315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure.
    Fu S; Chang Z; Luo L; Deng J
    Curr Top Med Chem; 2019; 19(20):1850-1866. PubMed ID: 31448711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.